355 research outputs found
Novel D-hordein-like HMW glutenin sequences isolated from Psathyrostachys juncea by thermal asymmetric interlaced PCR
New high-molecular-weight glutenin (HMW glutenin) sequences isolated from six Psathyrostachys juncea accessions by thermal asymmetric interlaced PCR differ from previous sequences from this species. They showed novel modifications in all of the structural domains, with unique C-terminal residues, and their N-terminal lengths were the longest among the HMW glutenins reported to date. In their repetitive domains, there were three repeatable motif units: 13-residue [GYWH(/I/Y)YT(/Q)S(/T)VTSPQQ], hexapeptide (PGQGQQ), and tetrapeptide (ITVS). The 13-residue repeats were restricted to the current sequences, while the tetrapeptides were only shared by D-hordein and the current sequences. However, these sequences were not expressed as normal HMW glutenin proteins because an in-frame stop codon located in the C-termini interrupted the intact open reading frames. A phylogenetic analysis supported different origins of the P. juncea HMW glutenin sequences than that revealed by a previous study. The current sequences showed a close relationship with D-hordein but appeared to be more primitive
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Objectives: To evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARDs). Methods: Adults with active AS who met modified New York criteria and had an IR to one or two bDMARDs (tumour necrosis factor or interleukin-17 inhibitors) were randomised 1:1 to oral upadacitinib 15 mg once daily or placebo. The primary endpoint was Assessment of SpondyloArthritis international Society 40 (ASAS40) response at week 14. Sequentially tested secondary endpoints included Ankylosing Spondylitis Disease Activity score, Spondyloarthritis Research Consortium of Canada MRI spine inflammation score, total back pain, nocturnal back pain, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index and Maastricht Ankylosing Spondylitis Enthesitis Score. Results are reported from the 14-week double-blind treatment period. Results: A total of 420 patients with active AS were randomised (upadacitinib 15 mg, n=211; placebo, n=209). Significantly more patients achieved the primary endpoint of ASAS40 at week 14 with upadacitinib vs placebo (45% vs 18%; p<0.0001). Statistically significant improvements were observed with upadacitinib vs placebo for all multiplicity-controlled secondary endpoints (p<0.0001). Adverse events were reported for 41% of upadacitinib-treated and 37% of placebo-treated patients through week 14. No events of malignancy, major adverse cardiovascular events, venous thromboembolism or deaths were reported with upadacitinib. Conclusion: Upadacitinib 15 mg was significantly more effective than placebo over 14 weeks of treatment in bDMARD-IR patients with active AS. No new safety risks were identified with upadacitinib.</p
Partial Wave Analysis of
BES data on are presented. The
contribution peaks strongly near threshold. It is fitted with a
broad resonance with mass MeV, width MeV. A broad resonance peaking at 2020 MeV is also required
with width MeV. There is further evidence for a component
peaking at 2.55 GeV. The non- contribution is close to phase
space; it peaks at 2.6 GeV and is very different from .Comment: 15 pages, 6 figures, 1 table, Submitted to PL
Evidence of Color Coherence Effects in W+jets Events from ppbar Collisions at sqrt(s) = 1.8 TeV
We report the results of a study of color coherence effects in ppbar
collisions based on data collected by the D0 detector during the 1994-1995 run
of the Fermilab Tevatron Collider, at a center of mass energy sqrt(s) = 1.8
TeV. Initial-to-final state color interference effects are studied by examining
particle distribution patterns in events with a W boson and at least one jet.
The data are compared to Monte Carlo simulations with different color coherence
implementations and to an analytic modified-leading-logarithm perturbative
calculation based on the local parton-hadron duality hypothesis.Comment: 13 pages, 6 figures. Submitted to Physics Letters
Effects of polysaccharide from Ophiopogon japonicus on immune response to Newcastle disease vaccine in chicken
Matter rogue wave in Bose-Einstein condensates with attractive atomic interaction
We investigate the matter rogue wave in Bose-Einstein Condensates with
attractive interatomic interaction analytically and numerically. Our results
show that the formation of rogue wave is mainly due to the accumulation of
energy and atoms toward to its central part; Rogue wave is unstable and the
decay rate of the atomic number can be effectively controlled by modulating the
trapping frequency of external potential. The numerical simulation demonstrate
that even a small periodic perturbation with small modulation frequency can
induce the generation of a near-ideal matter rogue wave. We also give an
experimental protocol to observe this phenomenon in Bose-Einstein Condensates
Search for the Chiral Magnetic Effect in Au+Au collisions at GeV with the STAR forward Event Plane Detectors
A decisive experimental test of the Chiral Magnetic Effect (CME) is
considered one of the major scientific goals at the Relativistic Heavy-Ion
Collider (RHIC) towards understanding the nontrivial topological fluctuations
of the Quantum Chromodynamics vacuum. In heavy-ion collisions, the CME is
expected to result in a charge separation phenomenon across the reaction plane,
whose strength could be strongly energy dependent. The previous CME searches
have been focused on top RHIC energy collisions. In this Letter, we present a
low energy search for the CME in Au+Au collisions at
GeV. We measure elliptic flow scaled charge-dependent correlators relative to
the event planes that are defined at both mid-rapidity and at
forward rapidity . We compare the results based on the
directed flow plane () at forward rapidity and the elliptic flow plane
() at both central and forward rapidity. The CME scenario is expected
to result in a larger correlation relative to than to , while
a flow driven background scenario would lead to a consistent result for both
event planes[1,2]. In 10-50\% centrality, results using three different event
planes are found to be consistent within experimental uncertainties, suggesting
a flow driven background scenario dominating the measurement. We obtain an
upper limit on the deviation from a flow driven background scenario at the 95\%
confidence level. This work opens up a possible road map towards future CME
search with the high statistics data from the RHIC Beam Energy Scan Phase-II.Comment: main: 8 pages, 5 figures; supplementary material: 2 pages, 1 figur
Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.
BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362
- âŠ